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Abstract
Background: Although evidence exists that regulatory T cells (Tregs) can suppress the effector phase of immune responses,
it is clear that their major role is in suppressing T cell priming in secondary lymphoid organs. Recent experiments using two
photon laser microscopy indicate that dendritic cells (DCs) are central to Treg cell function and that the in vivo mechanisms
of T cell regulation are more complex than those described in vitro.
Principal Findings: Here we have sought to determine whether and how modulation of Treg numbers modifies the lymph
node (LN) microenvironment. We found that pro-inflammatory chemokines—CCL2 (MCP-1) and CCL3 (MIP-la)—are secreted
in the LN early (24 h) after T cell activation, that this secretion is dependent on antigen-specific DC–T cell interactions, and
that it was inversely related to the frequency of Tregs specific for the same antigen. Furthermore, we demonstrate that
Tregs modify the chemoattractant properties of antigen-presenting DCs, which, as the frequency of Tregs increases, fail to
produce CCL2 and CCL3 and to attract antigen-specific T cells.
Conclusions: These results substantiate a major role of Tregs in LN patterning during antigen-specific immune responses.
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Introduction
The immune system has developed several sophisticated
regulatory mechanisms that ensure tolerance towards self-antigens
and moderate inflammation induced by pathogens and environ-
mental insults. Among these mechanisms, suppression of T cell
functions by regulatory T cells (Treg) is crucial and Tregs are now
considered as the primary mediators of peripheral tolerance.
Naturally-occurring Tregs are positively selected in the thymus,
presumably by self-antigens that remain to be defined, and express
the FoxP3 transcription factor, which is essential for their regulatory
function [1,2] but not for their lineage determination [3]. The role
of Treg cells inmaintainingtoleranceto self-antigensis evidenced in
mice and individuals that lack FoxP3 and that develop a profound
autoimmune-like lymphoproliferative disease [4,5]. However, Treg
cells may also block beneficial responses, as reported for antitumor
immunity[6], andinterfere withthecompleteremovalofpathogens
[7]. Thus, it is of obvious importance to define the mechanisms of in
vivo T cell regulation, not only to better understand the process of
peripheral tolerance but also to develop effective approaches for the
clinical manipulation of Treg cells.
Although evidence exists that Tregs can suppress the effector
phase of immune responses, it is clear that their major role is in
suppressing T cell priming in secondary lymphoid organs. A
considerable number of experiments performed in vitro have shown
that Treg cells depend on direct cell-cell contact to mediate their
inhibitory activity, and have suggested that the major mechanisms
described (inhibitory cytokines, cytolysis and metabolic disruption)
act directly on the effector T cell (reviewed in[8]). However, recent
intravital microscopy experiments have demonstrated that the
presence of Tregs in the lymph node (LN) decreases the frequency
of stable contacts between self-reactive T cells and dendritic cells
(DCs) that supposedly present the cognate antigen [9,10].
Furthermore, no detectable direct interaction between suppressed
T cells and Tregs was observed during the in vivo experiments; in
contrast, direct interaction between antigen-bearing DCs and
Tregs was reported, suggesting that the mechanisms of in vivo
regulation are much more complex than those described in vitro
and likely involve DCs.
Chemokines control homeostatic circulation of leukocytes as
well as their movement to sites of inflammation or injury. For
example, CCR7 and its ligands, CCL19 and CCL21, direct the
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and within lymph nodes. CCR5 and its ligands facilitate efficient
CD8 T cell priming within the LN [15]. CCL2, through its
receptor CCR2, can recruit monocytes, immature DC and natural
killer (NK) cells under inflammatory conditions [16,17,18,19,20].
Interestingly, it has been recently reported that ablation of
Tregs unexpectedly increases susceptibility to virus infection, as a
consequence of enhanced production of proinflammatory cyto-
kines and chemokines in the LN, paralleled by a reduced or
delayed recruitment of inflammatory DCs, NK and T cells to the
sites of infection [21]. It is thus conceivable that, in vivo, Tregs
modify the local lymphoid microenvironment and, consequently,
DC behavior or functions. To address this question in a setting
that would allow us to know what Tregs are responding to, we
used a TCR transgenic mouse model in which regulatory and
conventional T cells with the same antigen specificity develop.
Furthermore, this mouse model allows studying the effect of
tunable fluctuations in Treg number on the inflammatory LN
environment, a condition that may resemble what observed in
some pathological conditions (reviewed in [22]).
Materials and Methods
Ethics Statement
Procedures involving animals and their care conformed with
institutional guidelines (authorisation n. 11/2006-A from the
Italian Ministry of Health) in compliance with national (4D.L.
N.116, G.U., suppl. 40, 18-2-1992) and international law and
policies (EEC Council Directive 86/609, OJ L 358,1,12-12-1987;
NIH Guide for the Care and Use of Laboratory Animals, US
National Research Council 1996). All efforts were made to
minimize the number of animals used and their suffering.
Mice
BALB/c (H-2d) mice were from Charles River Laboratories
(Italy). TCR-HA transgenic mice expressing a TCRab specific for
peptide 111–119 from influenza virus hemagglutinin (HA)
presented by I-E
d have been previously described [23], are on
the BALB/c background and are referred to as single transgenic
(stg). These mice were crossed with mice expressing influenza HA
under the control of the ubiquitous pgk promoter to generate
TCR-HA x pgk-HA double-transgenic mice [24], referred to as
dtg. All mice were used between 5 and 8 weeks of age.
Antibodies and Reagents
The clonotypic 6.5 mAb, which recognizes the transgenic
TCR-HA, was produced in our laboratory and was used coupled
to biotin or PE. All other antibodies for flow cytometry were
purchased from BD Pharmingen. Cells were analyzed on a flow
cytometer (FACS Canto; Becton Dickinson). Cell sorting was
peformed using a FACS Aria (Becton Dickinson). Facs data were
analysed using Diva software and FlowJo software. LPS (Esche-
richia coli 026:B6) was purchased from Sigma-Aldrich. The HA
peptide (SVSSFERFEIFPK) was purchased from Invitrogen.
Cell Isolation and Preparation
For in vitro experiments, conventional (CD4
+CD25
26.5
+)o r
regulatory (CD4
+CD25
+6.5
+) T cells specific for HA were stained
with anti-CD4, anti-CD25 and 6.5 antibodies and sorted on a Facs
Aria (BD Biosciences).
For adoptive transfer experiments, T cells were obtained from
the LNs of stg or dtg mice, incubated with the biotinylated 6.5
mAb, and positively selected with anti-biotin MACS microbeads
(Miltenyi Biotec). Purity was always .85%.
Dendritic cells (DC) were obtained from the bone marrow of
BALB/c mice and were grown for 10 days in complete IMDM
supplemented with 30% supernatant of GM-CSF expressing
fibroblasts. In some cases, DCs were labelled with 7 mM 5- and 6-
(4-chloromethyl) benzoylamino-tetramethylrhodamine (CMTMR)
(Invitrogen) and pulsed with HA peptide (5 mg/ml) for one hour,
washed extensively in PBS and injected s.c. in the hind footpads.
In Vitro Proliferation and Regulation Assays
All assays were performed in complete IMDM (Gibco),
supplemented with 2-mercaptoethanol (Gibco) and 10% FCS.
FACS-sorted CD4
+6.5
+CD25
2 or CD25
+ T cells (2.5610
4)
obtained from stg or dtg mice were incubated with DCs
(1.5610
4) in flat bottom 96 well plates. In some wells, FACS-
sorted CD4
+6.5
+CD25
2 or CD25
+ T cells obtained from dtg mice
were added to CD4
+6.5
+CD25
2 from stg mice at a ratio of 1:1.
After 3 days of culture, supernatants were collected for the
quantification of cytokines and 1 mCi
3H-methyl-thymidine was
added for an additional 16 h. All conditions were performed in
triplicates.
Immunization and Adoptive Transfers
Stg or dtg mice were immunized with 0.5–1610
6 CMTMR
labelled DCs, loaded or not with peptide, or with soluble HA
peptide with LPS (1 mg HA peptide and 0.5–1 mg LPS per
footpad) by s.c. injection into the footpad. In adoptive transfer
experiments, CFSE-labelled 6.5
+ T cells from stg mice (1610
6
cells) were adoptively transferred by i.v. injection into BALB/c
recipient mice that had received or not 2610
6 6.5
+ T cells from
dtg mice 6–18 h earlier. Recipients were immunized as described
above. Immunized mice were sacrificed at different time points
and the popliteal draining LNs (dLNs) were collected and treated
with 1.6 mg/ml collagenase IV (Sigma-Aldrich) and 0.2 mg/ml
DNAse (Roche) at 37uC for 30 min. Cells were washed in PBS,
counted and stained with specific antibodies. Contralateral
popliteal or axillary lymph nodes were used as control non-
draining LN.
Cytokine and Chemokine Detection
Cytokine and chemokine concentrations were quantified from
supernatants of in vitro cultures or from homogenized LNs from
immunized mice, using the ELISA duoset kits (R&D Systems)
according to the manufacturer’s instructions.
Confocal Microscopy
BALB/c mice were adoptively transferred with CFSE-labelled
6.5
+ T cells from stg or dtg mice and one day later immunized
with HA-loaded CMTMR+ DCs in the hind footpad. After
24 hours, dLNs were recovered and immediately frozen in OCT.
10 mm cryostat sections were cut, fixed in formalin 4% for
10 min and rehydrated in PBS. The nuclei were counterstained
with Hoechst (1 mg/ml, Invitrogen) and the slides were mounted
with ProLong (Invitrogen). Acquisition of images was made by
confocal microscopy Fluoview FV1000 (Olympus, Tokio, Japan)
and an oil immersion objective (6061.4 NA Plan-Apochromat;
Olympus). To perform DC and T counts, random-picked
2506250 mm quadrants at 406 magnification containing at
least one DC were considered and the T/DC ratio was
calculated.
For CCL2 and CCL3 stainings, fixed 10 mm cryostat sections
were incubated with the primary biotinylated CCL2 or CCL3
(MIP-1a) antibodies (R&D Systems) and revealed with Alexa647-
streptavidin or Alexa647-anti-goat antibody respectively (Invitro-
Tregs and Chemokines
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secondary antibodies alone.
To perform colocalization analysis, the images were obtained
with a 6061.4 NA objective with a resolution of 8006800 and a
laser excitation at 405, 488, 543 and 633 nm. Differential
interference contrast (Nomarski technique) was also used. The
extent of co-localization of two given labels was measured using
the ‘Co-localization’ module of Imaris 5.0.1, 64-bit version
(Bitplane AG, Saint Paul, MN). For each data set, 10 individual
cells were analyzed for co-localization.
To quantify the labelling for CCL2 and CCL3, a ROI on
CMTMR
+ DCs was drawn and the parameter ‘Percentage of
material co-localized’, which includes both the number of voxels
and their intensities, was calculated.
Statistical Analysis
Results are expressed as means 6 standard deviation. Groups
were compared by using non-paired Student t test and the
nonparametric Mann-Whitney test. p values ,0.05 (*), 0.01 (**)
and 0.001 (***) were considered significant. For the analysis of
T:DC co-localization a non-parametric ANOVA test was
performed and the p value for the difference between the upper
two quartiles and the lower two quartiles of each sample was
determined by Dunn’s multiple comparison test. Statistical
analysis was performed using the Prism software (graphPad).
Results
TCR Transgenic Mice with Different Tconv:Treg Cell
Ratios
Mice expressing a transgenic TCR that is specific for a peptide
from the influenza virus hemagglutinin (HA), restricted to MHC
I-E
d molecules and recognized by the clonotypic antibody 6.5,
have been previously described [23,25]. In these mice, the
frequency of FoxP3
+ cells is low when gating among CD4
+6.5
+
cells (6.2+0.9%). When these TCR-HA single transgenic mice are
crossed to mice expressing HA under the ubiquitous pgk promoter
(TCR-HA x pgk-HA double transgenic mice), a high proportion of
CD4
+ T cells expressing the transgenic TCR in periphery are
CD25
+ and are capable of regulating HA-specific responses in vitro
and in vivo [24]. In agreement, the frequency of FoxP3
+ cells
among the CD4
+6.5
+ population is 8–10 times higher in double
transgenic (dtg) than in single transgenic (stg) mice (Fig. 1A).
CD4
+6.5
+CD25
2 cells from dtg mice, which represent the
majority of the FoxP3
2 population, can be considered as T
conventional (Tconv) cells, because they are capable of prolifer-
ating and secreting IFNc in response to various peptide doses and,
in contrast to their CD25
+ counterparts, do not suppress
proliferation of 6.5
+CD25
2 cells from stg mice (Fig. 1B).
We therefore used these mice (TCR-HA stg and TCR-HA x
pgk-HA dtg) to evaluate the effects of a ten-fold difference in the
Tconv:Treg cell ratio (15.262.4:1 in stg mice vs. 1.160.2:1 in dtg
mice) on the LN microenvironment and DC behavior.
Decreased Numbers of DCs in the Draining LNs Is
Associated to a High Frequency of Treg Cells
In order to address DC recruitment and retention within LNs
containing low or high frequencies of antigen-specific Treg cells,
1610
6 CMTMR-labelled, bone-marrow derived DCs that were
loaded or not with HA peptide were injected in the footpad of stg
or dtg mice. At various times after injection, draining popliteal
LNs (dLNs) were recovered and cells were analyzed by flow
cytometry.
In accordance with early studies [26], we found that in stg mice
antigen-loaded DCs migrate and accumulate in dLNs to a greater
extent than unloaded DCs (Fig. 2A). The absolute number of
antigen-loaded DCs recovered at day 1 from the dLNs of dtg mice
was significantly lower compared to that recovered from the stg
ones. This difference was also observed after two days (Fig. 2B)
and tended to disappear by day 4 (not shown). TCR-HA
transgenic mice contain some CD8
+ cells that express the
transgenic TCR and could be contributing to DC cytotoxicity.
To exclude this possibility, we performed annexin V staining on
dLN suspensions as well as TUNEL, caspase 3 and caspase 9
immunofluorescence on dLN tissue sections from stg and dtg mice
that received CMTMR-labelled DCs loaded with HA peptide. We
could not detect any significant apoptosis among CMTMR-
positive DCs injected into either recipient (Fig. S1) indicating that
the decreased number of HA-loaded DCs in the dLN of dtg mice
at days 1 and 2 was not due to increased DC apoptosis within the
draining lymph node.
Since at 48 h the total cellularity of the dLNs was increased in
the stg mice as compared to the dtg mice (5.4610
662.0 vs.
2.5610
660.2 respectively), and since no antigen-driven T cell
proliferation was observed between days 1 and 2 (Fig. S2), it is
conceivable that the differences observed between dtg and stg mice
may be explained by a defect in the recruitment of cells into the
dLN. Indeed, when compared to dLNs from dtg mice, dLNs from
stg mice that had received HA-loaded DCs showed not only
higher numbers of CMTMR
+ DCs, but also of CMTMR
2,
endogenous DCs (Fig. 2C). Furthermore, in the stg mice, the ratio
of MHC class II high/low DCs in dLNs changed significantly as
compared to non-draining LNs, indicating recruitment of
immature or semi-mature DCs (Fig. 2D). This effect was
suppressed in dtg mice, where the absolute numbers of
endogenous DCs recovered from the dLN was significantly
reduced compared to the stg mice. Similarly, the number of total
CD8
+ T cells at day 2 was significantly increased in the dLN of stg
mice (Fig. 2E).
These results suggest that, in the presence of a high frequency of
Tregs, recruitment of DCs and lymphocytes to the dLN is
decreased during the initial phases of the immune response.
Treg Frequency Determines the Chemokine
Microenvironment of dLNs
The results reported above, together with the recent report by
Rudensky and collaborators [21], prompted us to determine the
chemokine levels in the dLN of stg and dtg mice upon antigen-
specific immunization. To avoid biases due to the lower numbers
of HA-pulsed DCs observed in the dLNs of dtg mice (Fig. 2), we
decided to inject soluble peptide, which is able to travel via afferent
lymphatics to the dLN and can be presented by resident DCs [27].
LPS was co-injected with the peptide in order to induce activation
of DCs and achieve efficient T cell priming.
Starting from one day after injection, the size and weight of the
dLN were different in stg and dtg mice, with dLN from dtg mice
being smaller, likely due to reduced arrival of immune cells
(Fig. 3A). In agreement, we found that, at day 1, the
proinflammatory chemokines CCL2 and CCL3, but not CCL5,
were increased in the dLNs of stg mice, and that the values
returned to basal levels already at day 3 (Fig. 3B). Importantly, in
accordance with in vitro experiments recently reported [28], this
chemokine secretion was the result of antigen-specific DC -T cell
interactions, since LPS alone did not induce such an increase. In
contrast, when a similar analysis was performed in dtg mice
expressing higher frequency of Tregs, we found that the induction
Tregs and Chemokines
PLoS ONE | www.plosone.org 3 November 2009 | Volume 4 | Issue 11 | e7696Figure 1. Tconv:Treg ratio and their proliferative capacity in stg and dtg mice. (A) Cell suspensions obtained from the LNs of stg or dtg
mice were stained for CD4, 6.5, CD25 and FoxP3 and analysed by flow cytometry. Living cells were gated for CD4 and 6.5 expression. One
representative dot plot is shown. (B) LN cells from stg or dtg mice were stained and sorted by flow cytometry according to CD4, CD25 and 6.5
expression. 2.5610
4 sorted T cells were cultured in triplicate wells with 1.5610
4 DCs and different doses of HA peptide. After 70 h of coculture,
supernatants were collected for IFNc measurement and thymidine was added for an additional 16 h in order to measure proliferation (upper panels).
In parallel, the ability of CD25
2 vs CD25
+ dtg sorted cells to inhibit proliferation and IFNc production of naive HA-specific T cells (stg CD252) was
analyzed (lower panels). Shown is one out of three independent experiments that gave similar results. b.d.=below detection.
doi:10.1371/journal.pone.0007696.g001
Tregs and Chemokines
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suppressed, and this was not the case for CCL5 (Fig. 3B).
In order to eliminate the possibility that this difference in
chemokine production was simply due to lower numbers of HA-
specific Tconv cells in the dtg mice vs the stg mice, we performed
adoptive transfers of CFSE-labelled 6.5
+ cells from a stg mouse
into BALB/c mice, in the absence or the presence of an equal
number of 6.5
+ cells isolated from dtg mice. Moreover, in this case,
the ratio of Tconv:Treg cells is higher than that in the experiments
performed using dtg mice (2:1 versus 1:1). Adoptively transferred
mice were immunized as described above, and chemokine
production (Fig. 3C) and T cell activation in dLNs (Fig. S2) were
analyzed. In accordance with the results obtained with stg and dtg
mice, CCL2 production was significantly reduced when HA-
specific T cells were primed in the presence of HA-specific Tregs.
This was despite the fact that the percentage of CD69 positive cells
among CFSE
+ T cells and their early proliferative capacity were
not significantly altered by the presence of regulatory T cells (Fig.
S2), in agreement with previous data obtained using the same
transgenic model [24]. Interestingly, endogenous DC migration to
dLNs after 24 h of HA immunization was reduced in recipients of
dtg cells as compared to recipients of stg ones (3.6+0.9610
4 vs
7.1+3610
4, respectively; p,0.05).
It is important to underline that, whilst in the experiments
performed in the first part of our study (Fig. 2) we used antigen-
bearing non-activated DCs, in the experiments described above
(Fig. 3) we used LPS to activate endogenous DCs, thus suggesting
that the effect of Tregs on chemokine microenvironment can be
observed even in the presence of strong costimulatory signals.
Altogether, these results show that, during the early phases of an
immune response, antigen-mediated DC-T cell interactions in
LNs induce the production of pro-inflammatory chemokines that
are required for further recruitment of immune cells. In LNs,
Tregs counteract this priming-induced chemokine production and
thus limit the very early phase of the immune response.
Tregs Inhibit Antigen-Induced DC-T Cell Co-Localization
within the LN
It has been recently shown that CC chemokines like CCL2,
CCL3 and CCL4, produced in vitro during cognate T cell-DC
interactions, induce morphologic modifications and migration of
DCs, both required for efficient T cell priming [28]. Furthermore,
it was shown that CCL3 and CCL4 guide the recruitment of naive
CD8
+ T cells to sites of antigen-driven interactions between TLR-
activated DCs and CD4
+ T cells, optimizing memory CD8
+ T cell
responses [29]. In order to investigate whether the altered
chemokine microenvironment observed in the presence of high
Figure 2. Effects of Tregs on DC migration towards dLNs. DCs
were stained with CMTMR, loaded or not with HA peptide and injected
into the footpads of stg or dtg mice. dLNs were harvested at day 1 (A)
or day 2 (B–E) post-injection, collagenase-digested, and analysed by
flow cytometry to determine absolute numbers of CMTMR
+, transferred
(A, B) and CMTMR
2 CD11c
+, endogenous (C) DCs, the ratio of MHC class
II high/low CD11c
+ cells (D) and the absolute numbers of CD8
+ cells (E).
The figures shown correspond to pooled data from three independent
experiments; in each experiment two to four mice per group were used.
doi:10.1371/journal.pone.0007696.g002
Figure3.EffectsofTregsonchemokineproductionduringanimmuneresponse.Stgand dtgmicewere injected inthe footpad withHA peptide
(1 mg)togetherwith LPS(0.5–1 mg).ControlmicereceivedLPS aloneornothing.Miceweresacrificedat differenttimesafterinjection,as indicated.(A)dLNs
were weighed and (B) CCL2, CCL3 and CCL5 chemokine content after homegenization was determined by ELISA. Shown are the pooled data from two
independent experiments, with two to three mice per group in each experiment. (C) BALB/c mice were adoptively transferred with CFSE-labelled 6.5
+ cells
obtained from stg mice without or with equal numbers of 6.5
+ cells isolated from dtg mice. The mice were immunized as described above. dLN were
harvested and CCL2 amounts were determined by ELISA. Data from two pooled out of three independent experiments performed are shown.
doi:10.1371/journal.pone.0007696.g003
Tregs and Chemokines
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with T cells within the LN, we performed fluorescence microscopy
analyses of dLN sections. CFSE-labelled 6.5
+ T cells from stg or
dtg mice were adoptively transferred into BALB/c mice and, one
day later, CMTMR-labelled, HA-loaded DCs were injected in the
footpad of the recipient mice. Mice were sacrificed one day after
DC injection and the dLN were prepared for histology. CMTMR-
positive DCs distributed throughout the T cell zones of the LN
and many, but not all, were in the paracortex, as previously
described using different experimental conditions [30]. In mice
that had received T cells from the stg mice, confocal analysis of
dLN sections showed that HA-specific T cells and HA-loaded DCs
were in close proximity (Fig. 4A, left pannel). This co-localization
was antigen-driven since it was not observed in the contra lateral
dLN, where unloaded DCs were injected (Fig. S3). In contrast to
what was observed in recipients of stg cells, in mice that received T
cells from dtg mice, the majority of the HA-loaded DCs were not
in close proximity with the HA-specific T cells (Fig. 4A, middle
and right panels). In order to provide a quantitative estimate of this
result, the T cell/DC ratio was calculated throughout the LN
sections within 2506250 mm quadrants containing at least one red
DC (Fig. 4B). This analysis demonstrated that in the dLN of mice
that had received T cells from stg donors, the T cell/DC ratio was
close to 1 in all quadrants, whereas in LNs enriched with Tregs the
T/DC ratios were distributed over a range of values between 0
and 20. The means of the top two and bottom two quartiles of the
values for the stg mice were not significantly different, whilst in dtg
mice the difference was statistically significant (p,0.001, non-
parametric ANOVA), suggesting that the dtg-derived population
followed a bimodal distribution (Fig. 4B) with quadrants rich in T
cells but poor in DCs and other quadrants rich in DCs but poor in
T cells. This difference was not a reflection of an altered ratio of T
cells and DCs within the entire LNs of recipient mice having
received the dtg cells, because the total T cell/DC ratio, as
Figure 4. Effects of Tregs on antigen-specific DC-T cell attraction. CFSE-labelled 6.5
+ T cells obtained from stg or dtg mice were adoptively
transferred into BALB/c recipients. One day later, CMTMR-labelled, HA-loaded DCs were injected into the footpad. 24 h after DC transfer, mice were
sacrificed and dLNs were frozen and cut for histological examination. (A) Representative images of two independent experiments are shown. Bar,
70 mm. (B) Quantitative analysis of the experiment in (A) on two LN sections from mice that had received T cells from stg donors (stg 1 and stg 2) and
three LN sections from mice that had received T cells from dtg donors (dtg 1, dtg 2, dtg 3). Each dot represents the T cell/DC ratio (calculated as
described in the Methods) for a single 2506250 mm quadrant. A non parametric ANOVA test was used and the difference between the higher 50%
and the lower 50% values within each condition showed that there was no significant difference for the stg mice and a significant difference for the
dtg mice (p,0.001). (C) Tissue sections were stained for CCL2. Bar, 10 mm. (D) Mander’s co-localization coefficient was determined as described in the
Methods and was used to understand if CCL2 had been produced by DCs or T cells, in mice that had received T cells from stg donors. (E) The
‘‘percentage of material co-localized’’ was determined as described in the Methods and represents the percentage of DC material (voxel signal
intensity) that co-localizes with CCL2 in LN sections of mice that received T cells from stg or dtg donors.
doi:10.1371/journal.pone.0007696.g004
Tregs and Chemokines
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not significantly different between the two types of recipients (data
not shown).
Altogether, these results indicate that in the lymphoid
microenvironment, Tregs inhibit antigen-driven chemokine pro-
duction as well as co-localization of antigen-bearing DC and
antigen-specific T cells.
In order to determine the source of CCL2 production as well
as the main cellular target of Tregs during an antigen-specific
immune response, we performed CCL2 staining of the
histological sections shown above (Fig. 4C). CCL2 staining in
the dLN that had received cells from a stg mouse was evident
and mainly restricted to the cytoplasm of CMTMR-positive,
antigen-loaded DCs. This was confirmed by the co-localization
analysis expressed as Mander’s coefficient (Fig. 4D), which was
0.997 for the CCL2-DCs pair (with 1.0 being the maximal
co-localization) and 0.224 for CCL2-T cells (with 0 meaning no
co-localization at all). Thus, in our experimental conditions,
CCL2 was mainly produced and secreted by antigen-presenting
DCs and not by activated T cells. In LNs that had received cells
from dtg mice, CCL2 staining was restricted to antigen-pulsed
DCs too, but, in agreement with our ELISA data, it was
significantly reduced in intensity (Fig. 4E). A similar reduction
was observed in the case of CCL3 when antigen-loaded DCs
were analyzed in LNs that had received 6.5
+Tc e l l sf r o ms t go r
dtg mice (% of co-localized material: stg, 75.9765.51; dtg:
48.0763.54; p,0.01). In agreement with previous data [28],
CCL3 staining was not restricted to DCs only but detectable
also in T cells, although at lowers levels (Mander’s coefficient
for recipients of 6.5
+ T cells from stg donors: DCs, 0.9860.01;
T cells 0.7060.04; p,0.0001).
These results indicate that Tregs inhibit CCL2 and CCL3
production by antigen-presenting DC and thus limit recruitment
of inflammatory cells into the LNs and T – DC co-localization
within the LN.
Discussion
Regulated migration of T cells and DCs from the periphery to
and within the lymphoid tissues is a key element in the induction of
immune responses [31]. In vivo imaging experiments have shown
that lymphocytes entering the T-cell zones move randomly over
densely packed networks of dendritic cells (DCs) and fibroblastic
reticular cells (FRCs) [32,33]. This motility is driven by CCR7-
binding chemokines and may be pivotal for T cells to find their
proper partners among numerous other cells. Besides CCL21,
other chemokines produced in lymph nodes may coordinate
specific encounters between cells. Thus, CCL3 and CCL4 seem to
be involved in recruitment of naı ¨ve CD8
+ T cells, which can
upregulate CCR5 expression during inflammation, to sites where
they can receive help from CD4
+ T cells [34].
Here we show that inflammatory chemokines, such as CCL2
and CCL3, are produced during the early phases of an antigen-
specific immune response in vivo. Production of chemokines in the
lymphoid tissues is important to recruit other immune cells and
thus potentiate the response to antigens. Indeed, we found that the
presence of antigen-presenting DCs in LNs induces recruitment of
unloaded, immature or semimature DCs that substantially
contribute to the reported increase in total LN cellularity [26].
In accordance, it has been shown that sustained T cell activation
and proliferation require antigen presentation by migratory DCs
[35] and that the entrance of blood-derived, inflammatory DCs
into LNs depends on CCR2 [36]. We hypothesize that this
antigen-induced, chemokine-driven recruitment of immune cells
into the lymphoid tissue is one of the main targets of Treg action in
vivo. We found that Tregs inhibit the early chemokine production
occurring in LNs in response to antigen-specific DC-T cell
interaction. Accordingly, dLNs enriched in Tregs were less
efficient in recruiting inflammatory cells and in enhancing the
immune response.
These results are in agreement with a previous elegant study
showing that total ablation of polyclonal natural Tregs during viral
infection resulted in an increase of certain proinflammatory
chemokines within the dLNs, resulting in trapping of effector cells
within the LN and poor viral clearance at the infection site [21]. In
our study, we used a tunable antigen-specific approach that
allowed us to demonstrate in vivo that: i) the production of pro-
inflammatory chemokines is due to antigen-specific DC-T cell
interactions; ii) changes in the Tconv:Treg ratios have a strong
impact on the lymphoid chemokine microenvironment; iii)
chemokines released during antigen-driven interactions - at least
CCL2 - are produced by antigen-presenting DCs; iv) Tregs block
CCL2 production by antigen-presenting DCs, most likely
inhibiting their ability to recruit other inflammatory cells and to
co-localize with antigen-specific T cells within the LNs.
The fact that Tregs have a direct effect on the capacity of DCs
to secrete chemokines is extremely interesting, especially when
considering that, in our experimental systems, Tregs did not
significantly affect the very early T cell response, as measured by
up-regulation of the activation marker CD69. Although in vitro
polyclonal Tregs can inhibit the production of CCR5 ligands by
conventional T cells [37], our data indicate that, in vivo, the Treg
target is mainly represented by DCs. This is in agreement with
previous in vivo studies that have observed Treg-DC interactions
within LNs, but could not report evidence for Treg-Tconv stable
contacts [9,10].
Although the precise mechanism by which Treg cells affect
chemokine production induced by DC-T cell interactions remains
to be determined, our data are in accordance with recent views on
the mechanisms of regulatory T cells [8] indicating that DCs are
an important target for regulation in vivo.
Altered Treg frequencies in blood, LNs and peripheral tissues
have been reported in association with several pathological
conditions (reviewed in [38,39]). For example, cancer growth
induces expansion of the Treg population through several
mechanisms [40,41,42] and elevated Treg frequencies have been
observed in patients affected by various types of malignancies
(reviewed in [22]). On the other hand, several therapies are being
tested to promote Treg expansion, development and survival in
vivo, with the final aim of treating a variety of immunologic diseases
ranging from autoimmunity to transplantation to allergy and
asthma [43,44]. Our data indicate that by increasing the
Treg:Tconv ratio it is indeed possible to switch off the
inflammation associated to T cell antigen-recognition and thus
provide further scientific support to the development of Treg-
based therapies.
Supporting Information
Figure S1 Undetectable apoptosis among HA-loaded DCs
injected into stg and dtg mice. CMTMR-positive, HA-loaded
DCs were injected into the footpad of stg or dtg mice. 48 h later,
dLNs were recovered, frozen, fixed with PFA 4% and labelled
with the polyclonal antibodies for Caspase 3 and Caspase 9 (1:100,
Cell Signaling Technology) as well as with the Tunel assay
(according to the procedure suggested by the supplier, Roche).
Magnification 60X. Bar, 5 mm. The inset shows a representative
positive staining of a sporadic cell on the same section, although
Tregs and Chemokines
PLoS ONE | www.plosone.org 7 November 2009 | Volume 4 | Issue 11 | e7696these did not correspond to CMTMR-positive cells. Magnification
60X with zoom. Bar, 5 mM
Found at: doi:10.1371/journal.pone.0007696.s001 (2.00 MB TIF)
Figure S2 Poor co-localization of unloaded DCs and HA-
specific T cells. Mice were adoptively transferred with CFSE-
labelled 6.5+ cells and one day later were injected with CMTMR-
positive DCs that were loaded with the HA peptide (shown in
Figure 4) or not loaded, as control (shown here), in the contra-
lateral footpad. 24 h later, dLNs were recovered, frozen and cut
for histological examination. Shown is one representative dLN
having received unloaded DCs; the left hand panel shows the
internal region of the dLN while the right hand panel shows the
cortical region of the LN. Magnification 60X. Bar, 40 mm
Found at: doi:10.1371/journal.pone.0007696.s002 (0.19 MB TIF)
Figure S3 Poor co-localization of unloaded DCs and HA-
specific T cells. Mice were adoptively transferred with CFSE-
labelled 6.5 cells from stg mice and one day later were injected
with CMTMR-positive DCs that were loaded with the HA
peptide (shown in Figure 4) or not loaded, as control (shown here),
in the contra-lateral footpad. 24 h later, dLNs were recovered,
frozen and cut for histological examination. Shown is one
representative dLN having received unloaded DCs; the left hand
panel shows the internal region of the dLN while the right hand
panel shows the cortical region of the LN. Magnification 60X.
Bar, 40 mm
Found at: doi:10.1371/journal.pone.0007696.s003 (1.23 MB TIF)
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